TRANSAVE is a biotechnology company whose mission
is to improve the treatment of serious lung diseases through the company's next generation, proprietary liposomal delivery technology providing prolonged release of a drug in the lung while minimizing systemic exposure.

Transave is currently developing new therapies which may improve the therapeutic index for treating lung infections that have a pseudomonas component, such as cystic fibrosis and bronchiectasis, and enable non-toxic pulmonary delivery of siRNA molecules. All of our therapies are delivered via inhalation directly to the site of the disease.